People

Ania M. Jastreboff, MD, PhD is an Associate Professor in Medicine and Pediatrics at Yale School of Medicine. Dr. Jastreboff is a clinically active physician-scientist and international thought leader in the scientific development and clinical application of novel anti-obesity pharmacotherapeutics revolutionizing obesity treatment. As founding director of the Yale Obesity Research Center (Y-Weight), she is leading and shaping pivotal landmark studies of dual- and triple-receptor hormone agonists and NIH-funded studies investigating the physiology of obesity. She has served as lead investigator and author for trials investigating novel nutrient-stimulated hormone (NuSH)-based therapies for obesity including dual hormone receptor agonist, tirzepatide, a GIP/GLP-1 receptor agonist (Jastreboff, et al., NEJM, 2022 & NEJM, 2024) and triple hormone receptor agonist retatrutide, a GIP/GLP-1/Glucagon receptor agonist (Jastreboff, et al., NEJM, 2023). Trained in both adult endocrinology and pediatric endocrinology, she serves on the Board of Governance for The Obesity Society, as a director on the American Board of Obesity Medicine, developing Obesity Clinical Practice Guidelines, and as co-director of the Yale Center for Weight Management, where she sees patients and teach trainees. She is a highly sought after speaker, teaching internationally, nationally, and locally. She is also a compassionate advocate for patients with obesity, from grass-roots patient groups to interviews with Ms. Oprah Winfrey. Videos of Dr. Jastreboff speaking with Ms. Oprah Winfrey about obesity (YouTube podcast) The Truth about Obesity (posted Jan-14-2025)How People Treat You After Weight Loss (posted Jan-21-2025)What Exactly is Obesity? (posted May-10-2024) Videos of Dr. Jastreboff and colleagues from the NEJM about: - What causes obesity: https://www.nejm.org/doi/full/... - Supporting patients with obesity: https://www.nejm.org/doi/full/... - Medications and surgery for obesity treatment: https://www.nejm.org/doi/full/...Video of Dr. Jastreboff speaking at the Lincoln Center about the biology of obesity and anti-obesity medications for the Yale For Humanity Illuminated event (NYC - January 2025) Yale video with Dr. Jastreboff about anti-obesity medications and the biology of obesity. Podcast (Yale Talk) with the president of Yale University, Dr. Peter Salovey, speaking with Dr. Jastreboff. Clinically, Dr. Jastreboff specializes in sophisticated use of anti-obesity medication combinations to help patients reach their weight and health goals.

Pamela Hu MD is an Assistant Professor of Pediatrics in the Section of Diabetes, Endocrinology, and Metabolism at Yale University School of Medicine. She received her M.D. from George Washington University and completed her Pediatric residency and Pediatric Endocrinology fellowship training at Yale New Haven Children’s Hospital. She is board-certified in General Pediatrics, Pediatric Endocrinology, and Obesity Medicine. Dr. Hu’s primary interest is in working closely with families and colleagues to provide high quality clinical care for children with disorders of the endocrine system. She offers clinics in general endocrinology, metabolic bone, obesity, and type 2 diabetes. Dr. Hu’s research interests include the management of childhood obesity and its co-morbidities including type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). She also enjoys working on quality improvement projects to increase equitable access to healthcare.

Michelle Van Name, MD, is an Assistant Professor of Pediatrics in Endocrinology and Diabetes at Yale School of Medicine.  Dr. Van Name obtained her undergraduate degree at Boston College and studied medicine at SUNY Downstate. She then completed her residency training in Pediatrics at Yale as well as additional fellowship in Pediatric Endocrinology, after which she has remained on faculty at Yale. Dr. Van Name was drawn to pediatric medicine because she enjoys teaching children how they can improve their health.Her clinical interest is treating children with type 1 diabetes, type 2 diabetes, and obesity. She leads the adolescent bariatric surgery program for adolescents interested in sleeve gastrectomy for treatment of obesity and its related medical conditions.Dr. Van Name's research focuses on improving diabetes management in populations struggling to meet glycemic targets, including through the use of diabetes technology and other interventions.  Given her interest in both type 1 diabetes and obesity, she is also exploring the intersection of diabetes, obesity, and insulin resistance in adolescents. Further, she is working to determine if medications approved for adults to treat type 2 diabetes are safe and efficacious in children with type 2 diabetes.